PRDM15 and cancer: Indeed, this is what we observe in the in vivo mouse models where we have a substantial delay in lymphomagenesis (Fig. 3b), and mice succumb rarely to B-cell tumors (when tumors escape Prdm15 deletion), but rather to late onset T and non-B/T malignancies (Supplementary Fig. 4A and Supplementary Data 1).